GSTM1 and non-Hodgkin lymphoma: In the subanalysis of patients with non-Hodgkin lymphoma receiving cyclophosphamide–doxorubicin–vincristine–prednisolone (CHOP) ± rituximab, 67% of patients had Hb concentrations of 9–11 g/dL at the time of initiation of darbepoetin alfa [8].